Kornimate/medical-research-clean huggingface dataset:
effects of exercise and virtual reality on depression

Conditions: Symptoms of Depression

Summary: this study is evaluating the effects of riding on a cycle ergometer while experiencing virtual reality to determine its effect on mood.

adults (males and females) above the age of 18 yrs will be recruited to determine if they have symptoms of depression based on a questionnaire (center for epidemiologic studies - depression scale (ces-d). they will then complete a beck inventory before and after the exercise. participants will be divided into groups either having symptoms of depression or not. they will be randomized to ride on a cycle ergometer with or without using virtual reality (vr) that will allow them to view neighborhoods or parks during the exercise. the ergometer will be set at resistance raising the heart rate to 65% of their age-predicted heart rate maximum. they will ride for 20 min and then complete the beck inventory to determine any changes in their depressive symptoms.

Eligibility criteria:
inclusion criteria: * males and females over the age of 18 years * with or without symptoms of depression * physically inactive or sedentary (less than 30 minutes per day) * normal vision and no color blindness * no physical disorders such as walking with assistance exclusion criteria: * below the age of 18 years or over 65 years, * women who are pregnant * individuals who have been diagnosed with mental disorders * individuals with leg injuries * individuals with cardiac problems * individuals with a history of asthma * individuals with a body mass index over 30.
music therapy for post-cardiac surgery pain management

Conditions: Opioid Use

Summary: music therapy as a supplement to post surgery pain management in cardiac surgery patients following median sternotomy.

2. specific aims: 1. primary aim: to assess whether music therapy can decrease the amount of opioid type pain medications used. hypothesis: music therapy reduces the amount of opioid type pain medication used in management of post-operative pain and discomfort. 2. secondary aims: i. to identify the gender and age groups of patients who can benefit from music therapy as a supplement to post-operative pain management. hypothesis: majority of the population of patient benefits from music therapy as a supplement to postoperative pain management. ii. to assess whether music therapy can increase patient satisfaction. hypothesis: music therapy increases patient satisfaction.

Eligibility criteria:
inclusion criteria: * patients undergoing cardiac surgery via median sternotomy exclusion criteria: * emergency cases. * patients with hearing impairment. * patients with dementia or other mental status changes. * patients who are clinically unstable postoperatively. * patients who develop postoperative complications. * patients who are non-english speaking.
a phase ib/ii study of the combination of byl719 plus amg 479 in adult patients with selected solid tumors

Conditions: PIK3CA Mutated Advanced Solid Tumors; PIK3CA Amplified Advanced Solid Tumors

Summary: this was a multi-center, open-label, phase ib/ii study. the aim of the phase ib part was to estimate the mtd(s) and/or identify the recommended phase ii dose(s) (rp2ds) for the combination of byl719 and amg 479 (ganitumab), followed by the phase ii part to assess the clinical efficacy and to further assess the safety of the combination in selected patient populations. patients were to be treated until progression of disease, unacceptable toxicity develops, or withdrawal of informed consent, whichever occurred first. all patients were to be followed up. at a minimum, patients must have completed the safety follow-up assessments 30 days after the last dose of the study treatment.

this was a multi-center, open-label, phase ib/ii study. the aim of the phase ib part was to estimate the mtd(s) and/or identify the recommended phase ii dose(s) (rp2ds) for the combination of byl719 and amg 479 (ganitumab), followed by the phase ii part to assess the clinical efficacy and to further assess the safety of the combination in selected patient populations. the dose escalation part of the study were to be guided by a bayesian logistic regression model (blrm). once mtd/rp2d had been determined, patients were to be enrolled in two phase ii arms. patients with pik3ca mutated or amplified hormone receptor positive breast carcinoma were to be enrolled in arm 1; patients with pik3ca mutated or amplified ovarian carcinoma were to be enrolled in arm 2. patients were to be treated until progression of disease, unacceptable toxicity develops, or withdrawal of informed consent, whichever occurred first. all patients were to be followed up. at a minimum, patients must have completed the safety follow-up assessments 30 days after the last dose of the study treatment.

Eligibility criteria:
key inclusion criteria: * written informed consent. * patients aged ≥ 18 years (male or female). * patients with the following histologically/cytologically-confirmed advanced solid tumors with documented somatic pik3ca mutations or amplifications in tumor tissue: * hormone receptor positive breast carcinoma * ovarian carcinoma * other tumors upon agreement with sponsor * adequate organ function * negative serum pregnancy test key exclusion criteria: * patients with known history of severe infusion reactions to monoclonal antibodies. * patients with primary cns tumor or cns tumor involvement. * history of thromboembolic event requiring full-dose anti-coagulation therapy any time prior to enrollment. * clinically significant cardiac disease. * history of another malignancy within last 2 years. * pregnant or nursing (lactating) women.

Keywords: pik3ca mutation advanced solid tumor breast cancer ovarian cancer cancers with a mass bulky tumor nodule lump advanced cancer advanced solid malignancies
health and wellness in obesity

Conditions: Obesity; Overweight

Summary: the present study aims to explore the effects of a novel multidisciplinary non-pharmacological intervention designed to improve health parameters and well-being in overweight and obese women. the proposed program is health- and quality of life-oriented, without a focus on weight loss, following the philosophical principles from "health at every size", and may provide an alternative mode of intervention to the traditional one, which is focused on the concept of "weight loss at any cost". to evaluate the efficacy of the intervention, a mixed-method design combining both qualitative and quantitative assessments will be applied.


Eligibility criteria:
inclusion criteria: * overweight (bmi \> 25 kg/m²) * without using "anti-obesity" drugs * not engaged in other interventions to control weight exclusion criteria: * bmi \< 25 kg/m² * under pharmacological treatment * under any type of intervention to control weight * inability to exercise

Keywords: overweight exercise nutrition philosophy
a retrospective study of radiotherapy combined with egfr-tki for stage iii egfr mutant lung cancer

Conditions: The Primary Study Metric is Progression-free Survival (PFS)

Summary: objective: to investigate the efficacy and safety of radiotherapy combined with egfr-ki in the treatment of stage iii egfr mutant lung cancer. methods: stage iii egfr mutant lung cancer cases who underwent radiotherapy combined with egfr-tki from december 2014 to december 2022 at the people's hospital of laibin, the first people's hospital of yulin, the affiliated hospital of guilin medical college, and the park east hospital of guangxi medical university kaiyuan were collected, and the primary index of the study was progression-free survival (pfs), and the secondary indexes were objective remission rate, overall survival, recurrence pattern, and adverse events. survival analysis was performed using the kaplan-meier method with log rank test for univariate analysis and cox proportional risk model for multifactorial analysis of prognosis.


Eligibility criteria:
inclusion criteria: * ①patients diagnosed with lung cancer by pathology; ②genetic testing for egfr mutation type; ③compliance with the international eighth edition of lung cancer tnm stage iiia-iiic; ④treatment modality of radiotherapy + targeted therapy. ⑤eastern cooperative oncology group (ecog) physical status score ≤ 2 exclusion criteria: * (1) those who underwent surgery; (2) those who received chemotherapy. (3) combination of other serious diseases that affect survival.
endostar combination with chemotherapy and egfr-tki in lung cancer rechallenging treatment after acquired resistance.

Conditions: Lung Cancer

Summary: here we are going to find a method by using available multiple drugs including angiogenesis medicine - endostar to treat lung cancer patients who acquired resistence from egfr-tki but have responsed to it before.

lung cancer patients who received epidermal growth factor receptor tyrosine kinase inhibitors(egfr-tki) will acquiring resistance to the drug. this is a study of using endostar, an angiogentic medicine, combination with chemotherapy and egfr-tki in lung cancer rechallenging treatment after resistance of egfr-tki and progression disease.

Eligibility criteria:
inclusion criteria: * patients with pathologic confirmation of nsclc with tissue diagnosis or cytologic diagnosis, whose nsclcs are locally advanced or metastatic stage iii-b / iv adenocarcinoma, and are inoperable and incurable with radiotherapy. * life expectancy of at least three (3) months after the start of administration of the investigational drug. * eastern cooperative oncology group (ecog) performance score 0 to 2. * patients with at least one tumor lesion that can accurately be measured by ct or mri in at least one dimension with longest diameter to be recorded as no less than double the slice thickness and \>=10 mm. * patient received at least 6 months egfr-tki and show tumor progress * adequate hematologic hepatic and renal functions based on the normal conditions of chemotherapy * patient signed consent form and adherence and geographic location are liable to follow up exclusion criteria: * cns metastasis * active infection * bleeding tendency or blood coagulation dysfunction * history of neurological or psychiatric disorders, including epilepsy, or dementia * pregnancy or breast-feeding women * organ transplant long-term use of immunosuppressive drugs * arrhythmia need anti-arrhythmic treatment or other risk of heart disease * use other targeted drugs during the research * other conditions may not allowed to join in this study according to the researcher's judgment

Keywords: endostar angiogenesis egfr-tki lung caner
clinical effect of the axillary approach to glenoid fractures

Conditions: Fracture; Glenoid

Summary: glenoid fractures result in glenohumeral post-trauma arthritis and instability. operative treatment is indicated for severe fractures. the traditional deltopectoral approach, which requires detachment of the subscapularis, has many drawbacks, including loss of external rotation and suboptimal fixation. arthroscopic techniques also cannot allow anatomic reduction and biomechanical stability for large fractures. we describe an alternative approach that enters from the axilla through the interval between the rotator cuff and the inferior glenoid, neck and lateral border of the scapula without detachment of the rotator cuff.


Eligibility criteria:
inclusion criteria: * traumatic and closed fractures * fracture type conforms to ideberg ia classification or ao/ota f1.1 classification * fracture displacement ≥4mm, the area of involvement ≥20%. exclusion criteria: * severe multiple trauma * pathological fracture * unable to tolerate surgical treatment * the interval between injury and operation was \> 2 weeks
pyrotinib rechallenge in her2-positive metastatic breast cancer pretreated with pyrotinib and trastuzumab

Conditions: HER2-positive Breast Cancer; Metastatic Breast Cancer

Summary: pyrotinib is an oral tyrosine kinase inhibitor targeting both her-1 and her-2 receptors. this study is a randomized, open-label, multi-center, parallel design study of the combination of pyrotinib, trastuzumab and chemotherapy versus trastuzumab and chemotherapy in her2+ mbc patients, who have prior received trastuzumab and pyrotinib. patients will be randomized in a 2:1 ratio to one of the following treatment arms. arm a: pyrotinib + trastuzumab + chemotherapy, arm b: trastuzumab + chemotherapy. patients will receive either arm of therapy until disease progression, unacceptable toxicity, or withdrawal of consent.


Eligibility criteria:
inclusion criteria: 1. aged ≥18 and ≤75 years; 2. pathologically confirmed her2 positive patients with recurrence/ metastatic breast cancer: her2 ihc 3+, or her2 ihc 2+ and fish detection gene amplification; 3. history of trastuzumab-containing chemotherapy in neoadjuvant, adjuvant or recurrence/ metastatic setting; 4. history of pyrotinib-containing chemotherapy in neoadjuvant or recurrence/ metastatic setting; 5. previously reveived ≤2 systemic treatment in recurrence/ metastasis setting; (anti-her2 adcs such as t-dm1 is included in chemotherapy regimens, endocrine therapy alone is not included); 6. ecog performance status of 0 to 1; 7. according to recist 1.1, at least one extracranial measurable lesion exists； 8. signed informed consent. exclusion criteria: 1. patients with leptomeningeal metastasis or unstable brain metastasis; 2. history of neurological or psychiatric disorders; 3. second malignancies within 5 years, except for cured skin basal cell carcinoma, carcinoma in-situ of uterine cervix and squamous-cell carcinoma; 4. undergone major surgical procedures or significant trauma within 4 weeks prior to randomization, or expected to undergo major surgery. 5. factors influencing the usage of oral administration (e.g. unable to swallow, chronic diarrhea and intestinal obstruction, etc.); 6. history of allergies to the drug components of this regimen; 7. history of immunodeficiency, acquired or congenital immunodeficiency (hiv positive), history of organ transplantation; 8. any other situations judged by investigator as not suitable for participating in this study.
marginal evaluation of zirconia reinforced lithium disilicate partial coverage restoration of egyptian posterior teeth.

Conditions: Carious Teeth; Adaptation

Summary: objective: to evaluate the marginal adaptation of the zirconia reinforced lithium disilicate (vita ambria) glass ceramic inlay/onlay compared with lithium disilicate(ips emax press) glass ceramic inlay/onlay in decayed posterior teeth.

a randomized controlled clinical trial, a double-blind (patient and examiner) is conducted by one trained and calibrated operators who perform all restorative procedures. the restorations will be evaluated by a blind and calibrated two examiner using the fdi (world dental federation) criteria. a total of 25 subject will be randomly assigned to each group for a total of 50 subject. the randomization sequence will be generated (www.randomlists.com/team-generator) and to ensure the confidentiality of the allocation, this will be used opaque, sealed and numbered envelopes in series. these will be kept with an independent researcher for the moment of inclusion of the subjects. both groups will receive inlay/onlay preparation . digital impression will be taken, wax pattern for the inlay/onlay restoration will be designed and milled using cad/cam(computer-aided design/computer-aided manufacturing) software. after that, the wax pattern will be invested and final inlay/onlay restoration will be constructed from vita ambria and ips e.max press ingots according to manufacturing instructions.

Eligibility criteria:
inclusion criteria: * the patient is healthy. * 18-50 years old. * normal occlusion. * good oral hygiene. * tooth with complete root apex. * tooth with moderate coronal decay. exclusion criteria: * patient incapable of self-care, mental illness, undergoing radiotherapy, diabetic patient, allergy to one of the materials used, pregnancy, smoker, parafunctional habits, poor oral hygiene, severe periodontitis, tooth need vital pulp therapy or surgical crown lengthening or marginal elevation, tooth with enamel or dentin hypoplasia or hypocalcification, mallaligned or malformed teeth and adjacent or opposing teeth are missed.

Keywords: inlay, onlay, partial coverage,
safety and effectiveness of acthar gel in participants with rheumatoid arthritis

Conditions: Arthritis, Rheumatoid

Summary: this is a 2-part study to examine the effect of acthar gel in adult participants with rheumatoid arthritis (ra) with persistently active disease even after receiving two other treatments intended to modify the disease. part 1 is an open label period in which all eligible participants receive acthar gel for 12 weeks. after these 12 weeks of treatment with acthar gel, participants will be evaluated for treatment response using the das28-esr. participants who have achieved low disease activity (lda) will enter a double-blind randomized maintenance period (part 2) and be randomized in a 1:1 ratio to receive either acthar gel or matching placebo for an additional 12 weeks. a single participant might be involved in the trial for as many as 32 weeks.


Eligibility criteria:
inclusion criteria: * male or nonpregnant, nonlactating female subjects * meets criteria for definite rheumatoid arthritis as defined by 2010 american college of rheumatology (acr)/european league against rheumatism (eular) classification at screening * has active disease defined as a score of \>3.2 on das28-esr prior to study drug administration despite dual-dmard treatment * is on a stable dose of ≤ 20 mg per week of methotrexate for at least 8 weeks and a stable dose of an allowed dmard for at least 24 weeks prior to the screening visit * may also be on a stable dose of 10 mg or less of prednisone or other the dose equivalent of another corticosteroid for 4 weeks prior to study drug administration exclusion criteria: * has current rheumatoid disease or inflammatory joint disease other than ra * has any history of use of adrenocorticotropic hormone (acth) for the treatment of ra * has taken b-cell mediated therapies in the 6 months prior to screening * has hepatitis b, hepatitis c, history of tuberculosis (tb) or other contraindication as per the united states (us) prescribing information for acthar * has history of type 1 or type 2 diabetes * has any clinically significant infection

Keywords: persistent disease activity
myofascial release and foot mobility in basketball players: a randomized controlled trial

Conditions: Foot Deformities

Summary: the purpose of this study was to investigate the acute effects of myofascial release on foot mobility and sportive performance in basketball players with hypomobile feet. this study was designed as randomized controlled experimental research.

hypomobility in the foot structure causes functional limitations. these functional limitations affect the sportive performance negatively, especially in basketball where dynamic movements such as jumping and sudden change of direction are very intense. in this context, reducing hypomobility is important in terms of eliminating performance disorders caused by hypomobility. the purpose of this study was to investigate the acute effects of myofascial release on foot mobility and sportive performance in basketball players with hypomobile feet. this study was designed as randomized controlled experimental research. twenty-four male basketball players (23.46±2.81 years) participated in the study. athletes were first subjected to foot mobility, balance and vertical jump tests. then the participants were divided into two groups as myofascial release (mr) and placebo myofascial release (pmr). myofascial release was applied to the mr group and placebo myofascial release was applied to the pmr group. after the application, foot mobility and performance measurements were performed again and the results were analyzed. it was observed that there was a significant difference in right foot mobility (rfm), left foot mobility (lfm), vertical jump (vj) and dynamic balance (db) parameters after the application in mr group (p\ 0.05). the results of this study show that a single session of myofascial release applied to the plantar sole temporarily increased foot mobility and improved vertical jump and dynamic balance performance in basketball players with chronic hypomobility.

Eligibility criteria:
inclusion criteria: * basketball players who had hypomobility in at least one foot, had not had a serious foot or ankle injury in the last year, and had been actively licensed for the last five years were included in the study. exclusion criteria: * those who did not meet the inclusion criteria were excluded from the study.

Keywords: hypomobile feet basketball players myofascial release foot mobility performance
vienna hiv infection via sex study

Conditions: HIV Infections; HIV Pre-Exposure Prophylaxis; Sexually Transmitted Diseases; Gonorrhea; Chlamydia; Syphilis

Summary: the main objective of this prospective observational cohort study is to investigate the epidemiology, the risk factors and ultimately the incidence of novel hiv infections among individuals at high risk for acquiring hiv via sex practices.

we will include individuals at high-risk for hiv acquisition, i.e. hiv-negative msm and transgender individuals who (i) do not use condoms consistently with casual partners and/or with hiv-positive partners who are not on treatment and/or (ii) recently acquired an sti and/or (iii) recently used pep and/or (iv) frequently engage in 'chemsex' within the past 12 months important clinical information on possible vectors for transmission (including but not limited to high-risk sex practices and sexualized drug use), use of hiv pre-exposure prophylaxis, incidence of sexually transmitted infections will be assessed and laboratory parameters will be obtained from blood, urine and mucosal secretion.

Eligibility criteria:
inclusion criteria: 1. high risk for acquiring hiv defined as followed: hiv-negative msm and transgender individuals who (i) do not use condoms consistently with casual partners and/or with hiv-positive partners who are not on treatment and/or (ii) recently acquired an sti and/or (iii) recently used pep and/or (iv) frequently engage in 'chemsex'. 2. age \>18 years and \<100 years. 3. written informed consent for this registry study. exclusion criteria: 1. withdrawal of the written informed consent.
sleep at 30 degrees in glaucoma

Conditions: Glaucoma

Summary: this study is designed to investigate the effect of body posture (particularly when sleeping) on the pressure in the eye. the effect of body posture on progressive glaucoma (glaucoma where a significant change i.e. a disc hemorrhage has occurred) is not known. the study will involve being admitted to the sleep unit of the university health network at toronto western hospital for 1 night (14 hours). iop will be measured in both eyes every 2 hours with a tonopen, along with brachial blood pressure (bp), in the sitting position until the patients reach their normal sleep cycle time. patients will then be asked to sleep in either lying down or reclining at a 30 degrees position and have the iop measurements and brachial bp every 2 hours in that position. the same cohort of patients will then be invited for a repeat 14 hour iop and bp measurement but will change their position, i.e. sitting before will now be supine and vice versa.


Eligibility criteria:
inclusion criteria: * this pilot study included patients with progressive ntg or poag as evidenced by disc hemorrhage despite well controlled intraocular pressures (iop), who were able to sleep flat exclusion criteria: * any patients who were not able to sign a consent or lying flat during sleep

Keywords: progressive glaucoma despite controlled iop